Suppliers face moving targets
The post-genomics era hasn't been kind to the supplier space. Since Applied Biosystems Group announced in March 2001 that purchasers had reduced spending on capital equipment like its flagship ABI Prism 3700 DNA sequencer, other companies in both the instrument and reagents markets have reduced their top line expectations. Now a more complex picture is emerging: overall demand for instruments continues to look soft, while consumables are expected to show decent growth.
The numbers for 2002 paint a somewhat gloomy portrait, as revenues for most suppliers grew at rates below those seen in 2001 (see "Eroding Top Line"). But more important is what the numbers say about the future, and what's clear from conversations with various companies is that the needs